FOSUN PHARMA (02196.HK): Vice president Yuan Fangbing resigns
On 2 November 2026, FOSUN PHARMA (02196.HK) said vice president Yuan Fangbing resigned for personal reasons on 31 October, leaving no position at the group.
Key Highlights:
- The resignation took effect when the written notice reached the board on 31 October 2026.
- His original term would have expired on 23 June 2028.
NewTimeSpace News: On 2 November 2026, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (stock code: 02196) published an overseas regulatory announcement setting out its senior management resignation notice filed on the Shanghai Stock Exchange. On 31 October 2026 the board received a written resignation from Mr. Yuan Fangbing, who stepped down as vice president for personal reasons with effect upon delivery to the board.
Mr. Yuan's original term would have run to 23 June 2028. After resigning he will not hold any position at the listed company or its controlled subsidiaries, and he has no unfulfilled public commitments. The board thanked him for his work during his tenure as a senior management member.
- FOSUN PHARMA (02196.HK): Registration application for new specification of HLX14 denosumab biosimilar accepted by NMPA
- FOSUN PHARMA (02196.HK): FXS5626 Approved for Phase II/III Trial in Non-Segmental Vitiligo
- FOSUN PHARMA (02196.HK): Sells 6% Stake in India's Gland Pharma for Approximate USD 294 Million
- FOSUN PHARMA (02196.HK): Licensed drug weliteitumab injection (GR1803) granted conditional approval for relapsed or refractory multiple myeloma
- FOSUN PHARMA (02196.HK): Repurchases 217,000 H shares for approximately HKD 3.587 million
